137 related articles for article (PubMed ID: 15453881)
1. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder.
Cardozo L; Lose G; McClish D; Versi E
Acta Obstet Gynecol Scand; 2004 Oct; 83(10):892-7. PubMed ID: 15453881
[TBL] [Abstract][Full Text] [Related]
2. The use of two estrogen preparations (a combined contraceptive pill versus conjugated estrogen cream) intravaginally to treat urogenital symptoms in postmenopausal Thai women: a comparative study.
Chompootaweep S; Nunthapisud P; Trivijitsilp P; Sentrakul P; Dusitsin N
Clin Pharmacol Ther; 1998 Aug; 64(2):204-10. PubMed ID: 9728901
[TBL] [Abstract][Full Text] [Related]
3. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
Tseng LH; Wang AC; Chang YL; Soong YK; Lloyd LK; Ko YJ
Neurourol Urodyn; 2009; 28(1):47-51. PubMed ID: 19089890
[TBL] [Abstract][Full Text] [Related]
4. Estrogen therapy influence on periurethral vessels in postmenopausal incontinent women using Dopplervelocimetry analysis.
Kobata SA; Girão MJ; Baracat EC; Kajikawa M; Di Bella V; Sartori MG; Jármy-Di Bella ZI
Maturitas; 2008 Nov; 61(3):243-7. PubMed ID: 18845407
[TBL] [Abstract][Full Text] [Related]
5. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review.
Nelson HD
JAMA; 2004 Apr; 291(13):1610-20. PubMed ID: 15069049
[TBL] [Abstract][Full Text] [Related]
6. Combined Vaginal Pelvic Floor Electrical Stimulation (PFS) and Local Vaginal Estrogen for Treatment of Overactive Bladder (OAB) in Perimenopausal Females. Randomized Controlled Trial (RCT).
Abdelbary AM; El-Dessoukey AA; Massoud AM; Moussa AS; Zayed AS; Elsheikh MG; Ghoneima W; Abdella R; Yousef M
Urology; 2015 Sep; 86(3):482-6. PubMed ID: 26135813
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of estrogens for recurrent urinary tract infections: third report of the hormones and urogenital therapy (HUT) committee.
Cardozo L; Lose G; McClish D; Versi E; de Koning Gans H
Int Urogynecol J Pelvic Floor Dysfunct; 2001; 12(1):15-20. PubMed ID: 11294525
[TBL] [Abstract][Full Text] [Related]
8. [Basic principles of hormone replacement therapy in the postmenopause].
Dören M
Ther Umsch; 2000 Oct; 57(10):628-34. PubMed ID: 11081374
[TBL] [Abstract][Full Text] [Related]
9. [Postmenopausal estrogen therapy: pharmacological treatment or replacement of the lacking hormone?].
Lippert TH; Seeger H; Mueck AO
Dtsch Med Wochenschr; 1999 Oct; 124(42):1245-8. PubMed ID: 10572534
[No Abstract] [Full Text] [Related]
10. Does vaginal estriol make urodynamic changes in women with overactive bladder syndrome and genitourinary syndrome of menopause?
Matarazzo MG; Caruso S; Giunta G; Valenti G; Sarpietro G; Cianci A
Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():75-79. PubMed ID: 29367168
[TBL] [Abstract][Full Text] [Related]
11. Vaginal estrogen therapy is associated with increased Lactobacillus in the urine of postmenopausal women with overactive bladder symptoms.
Thomas-White K; Taege S; Limeira R; Brincat C; Joyce C; Hilt EE; Mac-Daniel L; Radek KA; Brubaker L; Mueller ER; Wolfe AJ
Am J Obstet Gynecol; 2020 Nov; 223(5):727.e1-727.e11. PubMed ID: 32791124
[TBL] [Abstract][Full Text] [Related]
12. Combined Tolterodine and Vaginal Estradiol Cream for Overactive Bladder Symptoms After Randomized Single-Therapy Treatment.
Ellington DR; Szychowski JM; Malek JM; Gerten KA; Burgio KL; Richter HE
Female Pelvic Med Reconstr Surg; 2016; 22(4):254-60. PubMed ID: 26945271
[TBL] [Abstract][Full Text] [Related]
13. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women.
Sumino H; Ichikawa S; Kasama S; Takahashi T; Kumakura H; Takayama Y; Kanda T; Kurabayashi M
Atherosclerosis; 2006 Dec; 189(2):436-42. PubMed ID: 16469323
[TBL] [Abstract][Full Text] [Related]
14. Oestrogens and overactive bladder.
Robinson D; Cardozo L; Milsom I; Pons ME; Kirby M; Koelbl H; Vierhout M
Neurourol Urodyn; 2014 Sep; 33(7):1086-91. PubMed ID: 23868110
[TBL] [Abstract][Full Text] [Related]
15. Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy.
Palacios S; Castelo-Branco C; Cancelo MJ; Vázquez F
Maturitas; 2005 Feb; 50(2):98-104. PubMed ID: 15653006
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study.
Santoro N; Allshouse A; Neal-Perry G; Pal L; Lobo RA; Naftolin F; Black DM; Brinton EA; Budoff MJ; Cedars MI; Dowling NM; Dunn M; Gleason CE; Hodis HN; Isaac B; Magnani M; Manson JE; Miller VM; Taylor HS; Wharton W; Wolff E; Zepeda V; Harman SM
Menopause; 2017 Mar; 24(3):238-246. PubMed ID: 27779568
[TBL] [Abstract][Full Text] [Related]
17. Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10μg estradiol on symptoms of vulvovaginal atrophy.
Archer DF; Labrie F; Montesino M; Martel C
J Steroid Biochem Mol Biol; 2017 Nov; 174():1-8. PubMed ID: 28323042
[TBL] [Abstract][Full Text] [Related]
18. Effect of transdermal estradiol and oral conjugated equine estrogen on C-reactive protein in retinoid-placebo trial in healthy women.
Wakatsuki A; Okatani Y; Fukaya T
Circulation; 2003 May; 107(18):e127-8; author reply e127-8. PubMed ID: 12742976
[No Abstract] [Full Text] [Related]
19. [Local estrogen therapy--clinical implications--2012 update].
Kokot-Kierepa M; Bartuzi A; Kulik-Rechberger B; Rechberger T
Ginekol Pol; 2012 Oct; 83(10):772-7. PubMed ID: 23383564
[TBL] [Abstract][Full Text] [Related]
20. Estriol, conjugated equine estrogens, and alendronate therapy for osteoporosis.
Terauchi M; Obayashi S; Aso T
Int J Gynaecol Obstet; 2006 Feb; 92(2):141-2. PubMed ID: 16305796
[No Abstract] [Full Text] [Related]
[Next] [New Search]
